Summary
Eric Minikel is a biomedical researcher and drug-development leader with 12+ years of experience focused on curing and preventing human prion diseases. As Director of Prion Therapeutic Science at the Broad Institute and co-founder/director of Prion Alliance, he leads an interdisciplinary program spanning preclinical therapeutics, biomarker discovery, human genetics, and regulatory and patient engagement. He completed a PhD in Biological and Biomedical Sciences at Harvard/Broad and serves on the neurology faculty at Massachusetts General Hospital, combining rigorous genetics and translational expertise with clinical perspectives. Eric is notable for pairing hands-on computational genetics and bioinformatics work with laboratory drug development—publishing methods and pipelines used to analyze exomes and RNA-seq for rare neurodegenerative disease research. His long-term, public-facing commitment includes advocacy and education through CureFFI.org and media engagement, reflecting a rare mix of scientist-advocate leadership. Colleagues describe him as mission-driven and unusually effective at bridging basic science, clinical translation, and community mobilization.
12 years of coding experience
7 years of employment as a software developer
MCP/MST, City Planning and Transportation, MCP/MST, City Planning and Transportation at Massachusetts Institute of Technology
BS, Chinese Language and Literature, BS, Chinese Language and Literature at University of Wisconsin-Madison
PhD, Biological and Biomedical Sciences, PhD, Biological and Biomedical Sciences at Harvard University
English, Chinese, Spanish, modern standard arabic